Taken collectively, the multidimensional benefits of enhanced PPARα activity provide compelling evidence that PPARα agonism is capable of addressing the complex nature of common retinal diseases beyond what is capable with anti-VEGF strategies [78,79,80]. The gene discussed is PPARA; the disease is Abnormal retinal morphology.